What We Know About Dr. Fauci Pleading the Fifth in Senate Hearing on Covid Origins
Sheryl Gay Stolberg and Benjamin Mueller / nytimes - In a three-hour Senate hearing this week, Dr. Fauci invoked his constitutional right to stay silent, leaving people confused about many of the issues raised.
AI Summary: A Senate hearing probing COVID-19’s origins put Dr. Anthony Fauci in the hot seat, with fierce questioning from senators including Rand Paul. At one point Fauci asserted his right against self-incrimination, sparking contentious exchanges, media analysis of his private notes and renewed debate about institutional decisions early in the pandemic.
- Plea of Fifth and Contempt Proceedings in Senate Probe (5)
- Private Notes, Cellphone Records and Political Fallout (3)
- Science, Media and Trust: Retractions and Expert Voices (3)
Plea of Fifth and Contempt Proceedings in Senate Probe
Private Notes, Cellphone Records and Political Fallout
Science, Media and Trust: Retractions and Expert Voices
Judge rejects states’ bid to pause Medicaid work requirements
Emily Olsen / healthcaredive - A federal judge this week said he wasn’t convinced that regulation detailing work requirements would cause irreparable harm to states. Still, the court will continue to hear the case.
AI Summary: A federal judge rejected a multi‑state request to pause implementation of Medicaid work requirement policies, finding insufficient grounds for an emergency stay. The ruling allows CMS guidance to remain in effect while legal challenges continue, leaving states and beneficiaries to navigate near‑term program changes amid ongoing litigation.
- AI and administrative responses to enrollment churn (3)
- Court rulings and Democratic opposition to the rule (3)
- Homeless people excluded from Medicaid exemptions (3)
- State rollouts, insurer readiness and early coverage losses (3)
AI and administrative responses to enrollment churn
Court rulings and Democratic opposition to the rule
Homeless people excluded from Medicaid exemptions
State rollouts, insurer readiness and early coverage losses
HHS to stop funding ‘dangerous’ life sciences research
Paige Twenter / beckershospitalreview - The federal government will stop funding what it determines to be “dangerous” gain-of-function research conducted in the U.S. and abroad after implementing a new policy. The “Policy for Stopping High-Risk Life Sciences Research” lands during broader uphea…
AI Summary: The federal government announced a new policy curbing federal funding for defined categories of high‑risk life‑sciences research, citing biosafety and biosecurity concerns. The move pauses support for experiments judged to pose elevated pandemic or containment risks, sparking debate about how to balance oversight, scientific progress and public safety without stifling useful innovation.
CMS locks in 2.3% inpatient hospital base pay increase, nudges back CJR-X Model start date
fiercehealthcare - The Inpatient Prospective Payment System (IPPS) final rule's base pay increase is slightly below what was proposed earlier this year, though the agency said it now expects the rule's changes to bring hospital payments hundreds of millions of dollars highe…
AI Summary: CMS finalized a 2.3% increase to the inpatient hospital base rate and pushed back the start date of the mandatory CJR‑X (comprehensive joint replacement) model, giving providers extra runway to adjust. The move eases short‑term reimbursement pressure and shifts timing for hospitals’ budgeting, reporting, and operational changes tied to the joint‑replacement mandate.
FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices
Jill Hughes / healthcaredive - Regulators say the telehealth company illegally shared patient health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”
AI Summary: Federal regulators have filed a lawsuit accusing telehealth and wellness firm Hims & Hers of improperly handling consumer data and engaging in misleading billing practices. The action alleges privacy violations and deceptive charges tied to subscription services, prompting scrutiny of digital health companies that promised convenience — and apparently delivered confusion instead.
CMS to end subsidies for Medicare drug plan premiums
Emily Olsen / healthcaredive - The CMS said the program, which went into effect last year to stabilize Part D premiums and enrollment, isn’t needed anymore. One researcher said some enrollees could see higher premium increases in 2027 as a result.
AI Summary: CMS will terminate its Part D premium stabilization subsidy, a program that helped blunt year-to-year premium swings for Medicare drug plans. The move removes a federal backstop aimed at keeping beneficiaries’ premiums lower, likely pushing costs onto enrollees and plan sponsors while igniting concerns about affordability for seniors and people on fixed incomes.
Centene boosts guidance amid $1.1B Q2 profit, ACA membership drop
Elizabeth Casolo / beckershospitalreview - Centene brought in a $1.1 billion profit for the second quarter of 2026, up from a $253 million loss at the same time last year, according to the company’s July 28 earnings report. Total revenue approached $53.6 billion for the quarter, up nearly 10% year…
AI Summary: Centene reported a dramatic Q2 turnaround, posting about $1.1 billion in profit and raising its 2026 guidance despite an ACA membership decline. Executives credited improved margins and operational adjustments for the rebound, signaling a healthier financial posture as the company navigates policy and enrollment headwinds.
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Rebecca Robbins / nytimes - Prediction markets on Kalshi and Polymarket now let people wager money on drug approvals. Kalshi also plans to allow bets on clinical trial results.
AI Summary: Betting platforms have started offering markets on clinical trial outcomes and FDA decisions, stirring alarms among regulators and researchers. Critics warn these markets could incentivize insider trading, leak-sensitive information, or distort trial conduct, prompting calls for oversight and clearer rules to protect scientific integrity and participant safety — because apparently Wall Street needed another hobby.
US court rules abortion pill restrictions 'unlawful'
medicalxpress - A federal court in Virginia has ruled that restrictions imposed by the U.S. drug regulator on the abortion pill mifepristone are "unlawful" and ordered the Trump administration to reconsider them.
AI Summary: A U.S. court ruled recent restrictions on the abortion pill unlawful, reaffirming FDA regulatory standards and restoring broader access. Industry groups filed briefs backing FDA oversight, warning that legal uncertainty would harm patients and research. The ruling calms access for now while legal and policy debates continue.
DHS finalizes 4-year visa limit for international physician training
Paige Twenter / beckershospitalreview - On July 17, the Department of Homeland Security finalized a rule capping U.S. stays for international students and exchange visitors at four years, ending the open-ended “duration of status” framework for medical trainees. Here are six things to know: 1. …
AI Summary: The Department of Homeland Security finalized new visa policies that alter the duration and structure of certain training‑related visas for international physicians, decoupling program length from visa terms. The changes aim to tighten immigration controls while raising concerns about workforce planning and the pipeline of internationally trained clinicians in U.S. health systems.
AHRQ terminates dozens of patient care research grants: Report
Elizabeth Gregerson / beckershospitalreview - HHS’ Agency for Healthcare Research and Quality has begun to terminate funding for research related to strengthening patient safety, care delivery, clinical practice and policy, and workforce training, according to a July 16 report from AcademyHealth. Aca…
AI Summary: The Agency for Healthcare Research and Quality has discontinued dozens of active research awards focused on patient care, citing programmatic changes and funding shifts. The abrupt terminations leave investigators scrambling and could slow progress on projects aimed at improving clinical practice and outcomes—proof that research pipelines are only as sturdy as their funding lines.
Molina Healthcare plans more marketplace exits as ACA segment falters
fiercehealthcare - Molina Healthcare is planning further reductions in its marketplace business as high costs continue to pressure that segment, the company's top brass told investors on Thursday morning.
AI Summary: Molina Healthcare announced plans to withdraw from additional Affordable Care Act marketplaces, citing financial challenges and market pressures. The move signals growing instability for some insurers in the ACA exchange space and could limit options for consumers in affected regions, while reigniting debates about market design and access.
- Hospitals and employers feel squeeze as uninsured rates climb (4)
- Insurers retreat from ACA exchanges, sparking debate over causes (4)
Hospitals and employers feel squeeze as uninsured rates climb
Insurers retreat from ACA exchanges, sparking debate over causes
US actions harm global efforts to prevent and treat HIV in dozens of countries, new report says
medicalxpress - The Trump administration's disruptions to a global AIDS relief program have forced organizations to close clinics, lay off staff and cut services, seriously impeding efforts to prevent and treat the disease in dozens of countries, a new report released Tu…
AI Summary: A new analysis concludes recent U.S. policy shifts have weakened international HIV prevention and treatment initiatives, disrupting funding flows and partnership stability. Public health experts caution the changes could reverse progress in vulnerable regions, urging policymakers to recalibrate support to sustain global gains against HIV/AIDS.
Children's cereals promise breakfast fun and nutrition, but are still high in sugar
medicalxpress - Many of us have grown up hearing the mantra that breakfast is the most important meal of the day, yet children's cereals fall short of that standard. That is the takeaway of new research analyzing child-targeted cereals in Canada.
AI Summary: Two investigative reports show major children's breakfast cereals remain high in added sugars despite branding that implies nutrition and fun. Public health advocates warn the products contribute to unhealthy diets in kids and call for clearer labeling and stricter marketing standards to parents and regulators.
D.C. appeals court sides with HHS in 340B drug discount program rebate challenge
fiercehealthcare - The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.
AI Summary: The D.C. appeals court sided with HHS in a legal challenge over 340B drug discount rebates, affirming federal authority over the program’s rebate models. The ruling preserves HHS policy changes that influence pricing and hospital participation, potentially reshaping pharmacy discounts and provider finances nationwide.
- Appeals court and federal rulings cement HHS 340B authority (3)
- CMS reimbursement shakeup: winners, losers and litigation fallout (3)
- HRSA’s revised 340B rebate pilot and oversight push (3)
Appeals court and federal rulings cement HHS 340B authority
CMS reimbursement shakeup: winners, losers and litigation fallout
HRSA’s revised 340B rebate pilot and oversight push
Key Republican Senator Says He Will Support Erica Schwartz for C.D.C. Director
Sheryl Gay Stolberg / nytimes - Senator Bill Cassidy, who is believed to hold the deciding vote in the Senate health committee for Dr. Erica Schwartz’s confirmation, had declined for days to say whether he would back her.
AI Summary: A leading Republican senator announced support for Dr. Erica Schwartz’s nomination to lead the CDC, bolstering bipartisan momentum amid a contentious confirmation process. The endorsement could smooth Senate consideration by narrowing opposition and signaling pragmatic cooperation on public health leadership.
6-year-old in China dies after experimental treatment, investigation finds, raising questions about the country's gene therapy regulations
livescience - A young girl in China died after being given an experimental gene therapy intended to treat a neurodevelopmental syndrome, an investigation by Science and Retraction Watch revealed.
AI Summary: An investigation found a six‑year‑old patient died following an experimental gene‑editing treatment in China, and that the fatality was not promptly disclosed. The case has reignited scrutiny of the country’s gene therapy oversight and raised urgent questions about trial transparency, consent and regulatory enforcement.
Measles cases set 35-year US record with months to go in 2026
medicalxpress - The United States has recorded more measles cases this year than in any year since 1991, with more than five months still left on the calendar.
AI Summary: Measles has surged to levels not seen in decades, prompting clinicians to describe chaotic front-line care and mounting pediatric distress. Public-health officials and hospitals are managing outbreaks, vaccination gaps and increased hospitalizations, while providers urge broader immunization and rapid containment to blunt what is becoming a national public-health headache.
Walid Kamoun: Breakthroughs Begin With the Right Questions and the Courage to Pursue Them
oncodaily - Walid Kamoun, Vice President, Global Head of R/D Oncology at Servier, shared The Nobel Prize’s post on LinkedIn, adding: “In this inspiring video, Tasuku Honjo reminds us that breakthrough innovation […]
AI Summary: Health officials confirmed a second fatality tied to a Legionnaires' disease outbreak in New York City, prompting intensified environmental testing and public‑health interventions. Authorities are tracing sources, inspecting water systems and issuing guidance to vulnerable populations while hospitals manage a surge of severe respiratory infections.
A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
Christina Jewett and Dana G. Smith / nytimes - Agency scientists are advising against allowing widespread use of several peptide injections. Robert F. Kennedy Jr., the health secretary, has said people should be free to experiment.
AI Summary: Federal regulators have zeroed in on a set of peptide injections gaining traction among wellness influencers and endorsed by RFK Jr., prompting internal debates about safety, evidence and regulation. FDA scientists are reviewing the products' claims and potential risks, setting up a clash between celebrity-driven demand and the agency’s evidence-based caution.
- Advisory panel votes to expand compounding despite safety warnings (4)
- FDA review and RFK Jr. clash over influencer‑favored peptides (4)
- Market hype and regulation: guidances, reporting and uncertainty (5)